1-azabicyclo[2.2.2]oct-3-yl [2-(biphenyl-3-yl)propan-2-yl]carbamate | 1401090-07-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-azabicyclo[2.2.2]oct-3-yl [2-(biphenyl-3-yl)propan-2-yl]carbamate
• 英文别名: 1-Azabicyclo[2.2.2]oct-3-yl[2-(biphenyl-3-yl)propan-2-yl]carbamate；1-azabicyclo[2.2.2]octan-3-yl N-[2-(3-phenylphenyl)propan-2-yl]carbamate
• CAS: 1401090-07-0
• 化学式: C₂₃H₂₈N₂O₂
• 分子量: 364.488
• InChiKey: BENIXRIDLPIJEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromophenyl)propan-2-yl]carbamate 、 苯硼酸 在 醋酸钯 作用下， 以gave the title compound as a white solid (379 mg, 64%)的产率得到1-azabicyclo[2.2.2]oct-3-yl [2-(biphenyl-3-yl)propan-2-yl]carbamate
  参考文献：
  名称：

  GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

  摘要：

  该发明涉及对葡萄糖酰胺合成酶（GCS）的抑制剂，可用于治疗代谢性疾病，如溶酶体贮存病，单独使用或与酶替代疗法联合使用，以及用于治疗癌症。

  公开号：

  US20160207933A1

文献信息

• [EN] METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME<br/>[FR] PROCÉDÉS DE RÉDUCTION DE LA CONCENTRATION EN GLYCOSPHINGOLIPIDES DANS LE TISSU CÉRÉBRAL ET PROCÉDÉS DE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES IMPLIQUANT CES DERNIERS
  申请人：GENZYME CORP

  公开号：WO2022024062A1

  公开（公告）日：2022-02-03

  Provided are methods for treating or preventing Parkinson's disease or dementia with Lewy Bodies in a human subject. The methods target lipid dysregulation in brain tissue of the subject and can, in particular, reduce the concentration of glycosphingolipids in brain tissue. The methods use quinuclidine compounds of formula (I), or pharmaceutically acceptable prodrugs or salts thereof. In particular, the human subject may be a carrier of one or more glucocerebrosidase 1 gene (GBA1) mutations, e.g. a heterozygous carrier of GBA1 mutations. Also provided are methods for assessing the effectiveness of treatments as described herein.

  提供了一种治疗或预防人类患帕金森病或Lewy体痴呆的方法。该方法针对患者脑组织中的脂质失调，并可特别降低脑组织中的糖脂类浓度。该方法使用公式（I）的喹啉类化合物或其药学上可接受的前药或盐。特别地，人类受试者可能是一种或多种葡萄糖酸酰基酶1基因（GBA1）突变的携带者，例如GBA1突变的杂合携带者。此外，还提供了评估本文所述治疗方法有效性的方法。
• Glucosylceramide synthase inhibitors
  申请人：GENZYME CORPORATION

  公开号：US09139580B2

  公开（公告）日：2015-09-22

  The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

  该发明涉及抑制葡糖鞘氨醇合成酶（GCS）的抑制剂，可用于治疗代谢性疾病，如溶酶体贮积症，单独或与酶替代治疗结合使用，并用于治疗癌症。
• US20140255381A1
  申请人：——

  公开号：——

  公开（公告）日：——
• METHODS FOR TREATING PROTEINOPATHIES
  申请人：Genzyme Corporation

  公开号：US20180036295A1

  公开（公告）日：2018-02-08

  This disclosure relates to a method of treating a proteinopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound. The disclosure also relates to a method of reducing, reversing or preventing the accumulation of protein aggregates in tissue of a subject diagnosed as having a proteinopathy, or being at risk of developing a proteinopathy, the method comprising administering to the subject an effective amount of a quinuclidine compound. Also disclosed is a pharmaceutical composition comprising a quinuclidine compound for use in said methods. The proteinopathy may be a synucleinopathy or a tauopathy, such as Parkinson's disease, Alzheimer's disease or dementia with Lewy bodies.
• BIOMARKERS OF PROTEOPATHIES AND USES THEREOF
  申请人：The Brigham and Women`s Hospital, Inc.

  公开号：US20200124624A1

  公开（公告）日：2020-04-23

  Provided herein are methods of determining the efficacy of a treatment for a proteopathy, diagnosing a proteopathy in a subject, determining a subject's risk of developing a proteopathy, determining the stage of a proteopathy in a subject, monitoring a proteopathy in a subject, selecting a treatment for a proteopathy for a subject, and selecting a subject for a clinical trial that include determining a level of at least one sphingolipid in a sample including a biological fluid from the subject.